AMSTERDAM, November 18 /PRNewswire-FirstCall/ --
- Glybera(R) Clinical Data Presented at Meeting of American Heart Association
Amsterdam Molecular Therapeutics (EuroNext Amsterdam: AMT), a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2009.
Q3 2009 Highlights - Jorn Aldag joins AMT as Chief Executive Officer - Glybera(R) remains on track for filing for regulatory approval in next three months
Jorn Aldag appointed as Chief Executive Officer
On September 24, 2009 AMT announced that Jorn Aldag, previously President
and CEO of Evotec AG, Germany, would join AMT as Chief Executive Officer as
of October 05, 2009. Jorn Aldag holds business degrees from the
At the same time, Prof. Sander van Deventer stepped down as interim CEO. He will continue to contribute his expertise and experience to AMT as Chairman of the Scientific Advisory Board and Business Consultant.
AMT's cash position(*) on September 30, 2009 amounts to EUR21.4 million
compared to EUR25.0 million on June 30, 2009. The cash outflow in the third
quarter of 2009, amounting to EUR3.6 million mainly represented operational
cash flow and is well within the guidance for this period. The Company is
adjusting its guidance for the year-end cash balance to approximately EUR17
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2009 PR Newswire.
All rights reserved